Showing results (101-110 of 114) with videos related to

Sort By:
Pageof 12
Clinical Genitourinary Cancer|December 29, 2019
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor GroupMarine Sroussi, Reza Elaidi, Aude Fléchon, et al.
European Urology|November 12, 2025
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 StudyRonan Flippot, Yann-Alexandre Vano, Cécile Dalban, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Bladder Cancer (Amsterdam, Netherlands)|August 12, 2024
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical CystectomyErik J van Gennep, Francesco Claps, Peter J Bostrom, et al.
European Journal of Cancer (Oxford, England : 1990)|January 16, 2014
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15)Gwenaelle Gravis, Patricia Marino, Florence Joly, et al.
The Lancet. Oncology|January 12, 2013
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trialGwenaelle Gravis, Karim Fizazi, Florence Joly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2022
Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark TrialsJoaquim Bellmunt, Ronald de Wit, Yves Fradet, et al.
European Urology|October 4, 2014
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic ModelGwenaelle Gravis, Jean-Marie Boher, Karim Fizazi, et al.
BJU International|February 7, 2023
Prognostic impact of variant histologies in urothelial bladder cancer treated with radical cystectomyFrancesco Claps, Maaike W van de Kamp, Roman Mayr, et al.
European Urology|October 28, 2017
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 TrialPernelle Lavaud, Gwenaëlle Gravis, Stéphanie Foulon, et al.
Pageof 12